FDA Clearance Tracker · K233606
ADVIA Centaur EBV-VCA IgM
Last checked: Nov 19, 2026Latest source record: Aug 7, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Aug 7, 2024
Substantially Equivalent
Time to decision
272 days
Received Nov 9, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class I
The decision
- FDA number
- K233606
- Device name
- ADVIA Centaur EBV-VCA IgM
- Applicant
- Biokit, S.A.
- Applicant location
- Lliçà DAmunt, Barcelona, ES
- Received
- Nov 9, 2023
- Decided
- Aug 7, 2024
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Epstein-Barr Virus, Other (LSE)
- Device class
- Class I
- Regulation
- 21 CFR 866.3235
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code LSE. The earliest in FDA's data is K872617, decided Jan 5, 1988.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K233606
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Biokit, S.A.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K243575 · Decided Feb 12, 2025 · 85 days after receipt
Device type: Enzyme Linked Immunosorbent Assay, Herpes Simplex Virus, Hsv-2 (MYF) · Laboratory Medicine & Pathology
K233605 · Decided Aug 7, 2024 · 272 days after receipt
Device type: Test, Antigen, Nuclear, Epstein-Barr Virus (LLM) · Laboratory Medicine & Pathology
K213987 · Decided Sep 20, 2023 · 639 days after receipt
Device type: Enzyme Linked Immunosorbent Assay, Herpes Simplex Virus, Hsv-1 (MXJ) · Laboratory Medicine & Pathology
4 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.